Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination

Imagem de Miniatura
Arquivos
art_GOMES_Immunoglobulin_A_Antibodies_Against_Myelin_Oligodendrocyte_Glycoprotein_in_2023.PDF (795.09 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER MEDICAL ASSOC
Autores
KULSVEHAGEN, Laila
LIPPS, Patrick
CAGOL, Alessandro
CERDA-FUERTES, Nuria
NEZIRAJ, Tradite
FLAMMER, Julia
LERNER, Jasmine
LECOURT, Anne-Catherine
SIEBENBORN, Nina De Oliveira S.
Citação
JAMA NEUROLOGY, v.80, n.9, p.989-995, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IMPORTANCE Differential diagnosis of patients with seronegative demyelinating central nervous system (CNS) disease is challenging. In this regard, evidence suggests that immunoglobulin (Ig) A plays a role in the pathogenesis of different autoimmune diseases. Yet little is known about the presence and clinical relevance of IgA antibodies against myelin oligodendrocyte glycoprotein (MOG) in CNS demyelination. OBJECTIVE To investigate the frequency of MOG-IgA and associated clinical features in patients with demyelinating CNS disease and healthy controls. DESIGN, SETTING, AND PARTICIPANTS This longitudinal study comprised 1 discovery and 1 confirmation cohort derived from 5 centers. Participants included patients with suspected or confirmed demyelinating diseases and healthy controls. MOG-IgA, MOG-IgG, and MOG-IgM were measured in serum samples and cerebrospinal fluid (CSF) of patients, who were assessed from September 2012 to April 2022. MAIN OUTCOMES AND MEASURES Frequency and clinical features of patients who were seropositive for MOG-IgA and double-seronegative for aquaporin 4 (AQP4) IgG and MOG-IgG. RESULTS After the exclusion of 5 participants with coexisting AQP4-IgG and MOG-IgA, MOG-IgG, and/or MOG-IgM, 1339 patients and 110 healthy controls were included; the median follow-up time was 39 months (range, 0-227 months). Of included patients with isolated MOG-IgA, 11 of 18 were female (61%), and the median age was 31.5 years (range, 3-76 years). Among patients double-seronegative for AQP4-IgG and MOG-IgG (1126/1339; 84%), isolated MOG-IgA was identified in 3 of 50 patients (6%) with neuromyelitis optica spectrum disorder, 5 of 228 patients (2%) with other CNS demyelinating diseases, and 10 of 848 patients (1%) with multiple sclerosis but in none of the healthy controls (0/110). The most common disease manifestation in patients seropositive for isolated MOG-IgA was myelitis (11/17 [65%]), followed by more frequent brainstem syndrome (7/16 [44%] vs 14/75 [19%], respectively; P =.048), and infrequent manifestation of optic neuritis (4/15 [27%] vs 46/73 [63%], respectively; P =.02) vs patients with MOG-IgG. Among patients fulfilling 2017 McDonald criteria for multiple sclerosis, MOG-IgA was associated with less frequent CSF-specific oligoclonal bands (4/9 [44%] vs 325/351 [93%], respectively; P <.001) vs patients with multiple sclerosis who were MOG-IgG/IgA seronegative. Further, most patients with isolated MOG-IgA presented clinical attacks after recent infection or vaccination (7/11 [64%]). CONCLUSION AND RELEVANCE In this study, MOG-specific IgA was identified in a subgroup of patients who were double-seronegative for AQP4-/MOG-IgG, suggesting that MOG-IgA may be a novel diagnostic biomarker for patients with CNS demyelination.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/57462
Referências
  1. Banwell B, 2023, LANCET NEUROL, V22, P268, DOI 10.1016/S1474-4422(22)00431-8
  2. Breedveld A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00553
  3. Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X
  4. Marignier R, 2021, LANCET NEUROL, V20, P762, DOI 10.1016/S1474-4422(21)00218-0
  5. O'Connor KC, 2007, NAT MED, V13, P211, DOI 10.1038/nm1488
  6. Pedreño M, 2019, MULT SCLER RELAT DIS, V28, P230, DOI 10.1016/j.msard.2019.01.007
  7. Pröbstel AK, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc7191
  8. Pröbstel AK, 2011, NEUROLOGY, V77, P580, DOI 10.1212/WNL.0b013e318228c0b1
  9. Pröbstel AK, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0256-1
  10. Prüss H, 2012, NEUROLOGY, V78, P1743, DOI 10.1212/WNL.0b013e318258300d
  11. Sabatino JJ, 2019, NAT REV NEUROSCI, V20, P728, DOI 10.1038/s41583-019-0233-2
  12. Schumacher H, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000569
  13. Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2
  14. Wilhelm I, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1143544
  15. Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOF
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/33
Artigos e Materiais de Revistas Científicas - LIM/45
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - LIM/62